Biological determinants of endocrine resistance in breast cancer.
about
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1Activation of rapid oestrogen signalling in aggressive human breast cancersCholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancerBreast cancer stem-like cells: clinical implications and therapeutic strategiesMechanisms of oestrogen receptor (ER) gene regulation in breast cancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsRoles for miRNAs in endocrine resistance in breast cancerInsights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast CancerEstrogen receptor degradation: a CUE for endocrine resistance?Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsCannibalism, cell survival, and endocrine resistance in breast cancerCooperating transcription factors mediate the function of estrogen receptorClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerMinireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancersAutophagy and endocrine resistance in breast cancerPatient-derived xenograft models of breast cancer and their predictive powerBreast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseAntiestrogens: structure-activity relationships and use in breast cancer treatmentFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2Cyclin D as a therapeutic target in cancerPELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinomaPELP1: a review of PELP1 interactions, signaling, and biologySignificance of ER-Src axis in hormonal therapy resistanceProgesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexesAssociation of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistanceThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisTamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerInduction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective studyIntegration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancerAnalysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell linesIntegrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancerDeciphering the divergent roles of progestogens in breast cancer.Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancerTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
P2860
Q21563388-87562661-328D-47B5-83DB-DE9C57CD31C8Q24300885-B618B42D-B0E3-46D7-9853-96BACA53ADD1Q24658633-DA45D972-C3F7-4049-A264-C729E587D544Q26752170-4C4EA7FC-4817-4DCF-86B0-0E50CD0C63C2Q26765380-02C52617-4D65-4D5C-AE6E-4827B4F8FA4DQ26775361-A64D433C-FB6A-4166-B039-5CBC2CBB07FAQ26782449-EF1F56A1-3595-4811-A317-AEEF4475C909Q26783076-85651E0B-62ED-4111-9C78-0B6DDC8F2CD2Q26795488-C089F82F-E399-4097-B807-92979BB03AF3Q26830072-9B46DAC0-E3F4-4BCE-B600-77FC88940FE3Q26995549-CC9C13FC-FE87-4E0B-81DA-D6D40306FE2DQ26995731-AC30F336-07B0-4F29-8ED9-B435911C0E5DQ26996464-8A85CA33-42CB-4287-9BB1-27EC92683284Q27001170-B1E90AE7-BD5E-42BF-A301-6E15F5398744Q27001260-095FAB35-704C-4111-84F7-569908BD0715Q27016106-E5F43B27-0B46-42D7-BEA0-817C407C8841Q27023375-5A1C7813-4A05-41A8-9B5C-006E3AE705E8Q27026531-9649F49D-DE1C-4D17-A20A-1D0485F6D0C1Q27316481-EC04F992-97CD-4B90-9F8D-AC1386C4B666Q27342622-24C341BD-14EF-4EFC-BBED-3AB41453117DQ27694612-F2D1EFFE-ACCD-456D-9618-3FE884FE8F78Q28077245-2B48E134-7C35-4743-944A-22FA7F72FAA9Q28084982-BD5DBF47-06AF-431B-BF06-F46CC5644830Q28085004-AE7A004A-2783-4F61-AC6F-13CBD00B67D2Q28242623-A8726074-1D02-467C-9921-6CFDB8B249D8Q28251097-97B6EF95-6A15-48E6-B392-C7DA27C59597Q28296277-C7978A78-A5E8-49F6-9989-086B63CA6845Q28301805-BE84A93A-4D59-45AC-AB91-33FF39FB7F0EQ28306753-FC7F0F1D-BC4D-4A75-9810-FBDA838B591CQ28308160-BBEE2DED-0C07-4954-ACC8-E9A27D31EDF0Q28388257-5CF2E3E0-B9BA-49E2-B1D0-AA262258DE9FQ28481232-2C2E88B3-C8B7-4B04-A685-97271244C335Q28538654-4F1278E1-A07F-4CAD-BF91-9CA6ECE58978Q28538685-199A318A-A968-4D61-A6F9-0BB66029FD92Q28603678-C1A2E8A7-80C5-4066-8891-D001896594E0Q28816965-430AC2E2-4F0E-49E2-9295-2265C177548AQ30240711-1084C2E4-1F13-4B85-A8C2-0C9F781E95A0Q30245184-AC42E0ED-2FE0-4027-B665-B7513CEC8001Q30408963-34569FDC-55DF-4868-988C-FFF5B1413C1EQ30419997-623BD497-37D1-4CA0-AD43-95719C5C54EF
P2860
Biological determinants of endocrine resistance in breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biological determinants of endocrine resistance in breast cancer.
@en
Biological determinants of endocrine resistance in breast cancer.
@nl
type
label
Biological determinants of endocrine resistance in breast cancer.
@en
Biological determinants of endocrine resistance in breast cancer.
@nl
prefLabel
Biological determinants of endocrine resistance in breast cancer.
@en
Biological determinants of endocrine resistance in breast cancer.
@nl
P356
P1476
Biological determinants of endocrine resistance in breast cancer.
@en
P2093
Elizabeth A Musgrove
Robert L Sutherland
P2888
P304
P356
10.1038/NRC2713
P407
P577
2009-09-01T00:00:00Z